Join
Live feed
·
PRReleasevia Quantisnow
Eledon Pharmaceuticals Inc. logo
NewcelX Ltd. logo

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

ByQuantisnow·Wall Street's wire, on your screen.
ELDN· Eledon Pharmaceuticals Inc.NCEL· NewcelX Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ELDN (Eledon Pharmaceuticals Inc.), NCEL (NewcelX Ltd.) and more on Quantisnow.